Regenxbio said its Duchenne muscular dystrophy gene therapy met the pivotal trial bar by producing sufficiently high levels of a miniaturized muscle protein, setting up an FDA submission path. The company’s update adds to ongoing momentum for exon-skipping and gene therapy competitors while keeping focus on efficacy thresholds tied to biomarker expression. Notably, the filing timeline targets a US decision window in the company’s later planning, with Regenxbio signaling that the dataset aligns with accelerated approval criteria. The company positioned the program as a potentially safer alternative in an area where prior safety concerns have shaped both regulatory and clinical execution. For developers, the report underscores how protein expression biomarkers and clinical safety signals continue to drive decision-making toward regulatory review in rare neuromuscular indications.